Skip to the map

Big pharma in PDAC

34 of the 50 largest pharma companies have at least one PDAC activity: 392 programs, deals, investments and trial collaborations.

Timeline

Pharma 50 = the 50 largest pharma companies by prior-year prescription revenue (Pharm Exec Top 50 (2026, by 2025 prescription sales)). Subsidiaries, acquired companies and venture arms count for their parent while the link held. Click a company in “Involvement by company” to focus every view on it.

Show:
Drug typeSmall moleculeOligonucleotideGene therapy / editingAntibody / biologicUndisclosedRepurposing
StatusActive (filled)Completed (hollow with ✓)Ended (hollow)Discontinued (✕)Unknown: possibly inactive (dashed)Click a mark for details
Activity · date used
In-house programfirst public evidence
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Acquired programdeal announcement
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Partnershipstart
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Discontinued programstop date, else last evidence
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Academic trial supporttrial start
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Investmentround close
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Generics of the standard-of-care drugapproval
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Involvement by company

Drug typeSmall moleculeOligonucleotideGene therapy / editingAntibody / biologicUndisclosedRepurposing
StatusActive (filled)Completed (hollow with ✓)Ended (hollow)Discontinued (✕)Unknown: possibly inactive (dashed)Click a company to focus every view; a mark for details
Pharma activities by company and activity type
Company
1
24
2
4
3
5
4
40
5
35
6
25
7
29
8
19
9
22
10
43
12
15
13
11
14
5
15
5
16
4
17
10
19
1
20
7
21
9
22
3
24
4
25
6
26
4
30
4
31
2
34
1
35
5
37
3
38
5
40
1
41
6
43
12
44
5
49
18

Programs, deals and trial support

Drug typeSmall moleculeGene therapy / editingAntibody / biologicUndisclosedRepurposing
StatusActive (filled)Completed (hollow with ✓)Ended (hollow)Discontinued (✕)Unknown: possibly inactive (dashed)Click a chip for details
Pharma programs, deals and trial support by activity type (rows) and stage (columns)
ActivityPreclinicalINDPhase 1Phase 2Phase 3+ApprovedStage not stated
In-house program
Acquired program
Partnership
Discontinued program
Academic trial support
Generics of the standard-of-care drug

Investments

Drug typeSmall moleculeOligonucleotideGene therapy / editingAntibody / biologicUndisclosed
StatusActive (filled)Ended (hollow)Click a chip for details
Pharma investments by round stage
ActivityFounding & seedSeries ASeries BSeries C & later privateRound not disclosed
InvestmentAmount = total round size